Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B13 | Q7Z5P4 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 8/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972329 | 0.85 | PTGES (0.46) | TP53PTGES | |
| SCHEMBL1972248 | 0.85 | PTGES (0.44) | KCNH2TP53PTGESGLS | |
| SCHEMBL1975367 | 0.84 | NPC1 (0.43) | PTGESMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL1977350 | 0.84 | KDM4E (0.54) | POLBMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL1977047 | 0.81 | HSD17B13 (0.44) | HSD17B13KCNH2PTGESADORA2A | |
| SCHEMBL1966890 | 0.81 | POLB (0.51) | PTGESPOLBMEN1MAPTKMT2A | |
| SCHEMBL13392964 | 0.80 | MAPK14 (0.50) | PTGESMEN1KMT2A | |
| SCHEMBL1972725 | 0.80 | KMT2A (0.43) | PTGESMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL1972457 | 0.80 | HSD17B13 (0.46) | HSD17B13TP53PTGESADORA2AGLS | |
| SCHEMBL16364047 | 0.80 | PTGES (0.45) | KCNH2PTGESPOLBMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334652-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-06-22 | — | — | EP | claimed |
| US-8916599-B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2014-12-23 | — | — | US | disclosed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | HSD17B13 4807/4885KCNH2 2356/4885TP53 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.